Non-alcoholic steatohepatitis (NASH) is a common and severe chronic disease characterized by excessive fat accumulation and inflammation in the liver, which can progress to liver fibrosis, cirrhosis, and liver necrosis. The NAC-NASH I model and NAC-NASH II model, developed based on the NAC-Organ technology, can simulate hepatocellular steatosis, inflammatory response, and fibrosis proliferation. The NASH model II can simulate the pathological distribution of hepatic stellate cells, forming a pseudo-lobule structure and simulating drug delivery blockade.

Application：Screening of therapeutic drugs for NASH
Efficient in vitro validation of NASH drugs using the 3D NAC-NASH model takes only 4 weeks from modeling to drug detection data analysis.

Application：Target research for NASH treatment
Using a humanized in vitro 3D NASH model, it has been confirmed that overexpression of TrkB in cells can inhibit the activation and proliferation of hepatic stellate cells, leading to alleviation of fibrosis. These findings are highly consistent with in vivo research results.